182 related articles for article (PubMed ID: 38494109)
1. The molecular crosstalk of the hippo cascade in breast cancer: A potential central susceptibility.
Parambil ST; Antony GR; Littleflower AB; Subhadradevi L
Biochimie; 2024 Jul; 222():132-150. PubMed ID: 38494109
[TBL] [Abstract][Full Text] [Related]
2. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
3. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
6. An overview of signaling pathways regulating YAP/TAZ activity.
Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
[TBL] [Abstract][Full Text] [Related]
7. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
8. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
9. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER
Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL
Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640
[TBL] [Abstract][Full Text] [Related]
12. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
13. Hippo signalling maintains ER expression and ER
Ma S; Wu Z; Yang F; Zhang J; Johnson RL; Rosenfeld MG; Guan KL
Nature; 2021 Mar; 591(7848):E1-E10. PubMed ID: 33658690
[No Abstract] [Full Text] [Related]
14. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer.
Shen J; Cao B; Wang Y; Ma C; Zeng Z; Liu L; Li X; Tao D; Gong J; Xie D
J Exp Clin Cancer Res; 2018 Jul; 37(1):175. PubMed ID: 30055645
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
16. A Non-Canonical Hippo Pathway Represses the Expression of ΔNp63.
Low-Calle AM; Ghoneima H; Ortega N; Cuibus AM; Katz C; Prives C; Prywes R
Mol Cell Biol; 2024 Jan; 44(1):27-42. PubMed ID: 38270135
[TBL] [Abstract][Full Text] [Related]
17. PI3K Positively Regulates YAP and TAZ in Mammary Tumorigenesis Through Multiple Signaling Pathways.
Zhao Y; Montminy T; Azad T; Lightbody E; Hao Y; SenGupta S; Asselin E; Nicol C; Yang X
Mol Cancer Res; 2018 Jun; 16(6):1046-1058. PubMed ID: 29545474
[TBL] [Abstract][Full Text] [Related]
18. Insights into recent findings and clinical application of YAP and TAZ in cancer.
Franklin JM; Wu Z; Guan KL
Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
[TBL] [Abstract][Full Text] [Related]
19. The emerging roles of YAP and TAZ in cancer.
Moroishi T; Hansen CG; Guan KL
Nat Rev Cancer; 2015 Feb; 15(2):73-79. PubMed ID: 25592648
[TBL] [Abstract][Full Text] [Related]
20. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
